NASDAQ:IDRA - Idera Pharmaceuticals, Inc.
$2.85
 $-0.16
-5.32%
4:20PM EDT
2019-02-22
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IDRA     avg for
industry  
  avg for
sector  
42 stocks weight:  28. 06   0. 00   0. 00  
42 stocks rank:  3. 34 K 2. 00 K 1. 08 K
# analyst opinions:  6. 00   14. 68   14. 18  

quick ratio:  8. 01   5. 17   1. 75  
current ratio:  8. 25   5. 48   2. 10  

target price low:  4. 46   90. 05   118. 16  
target price avg:  1. 83   115. 98   142. 03  
target price high:  3. 20   141. 44   162. 86  
1-yr high:  16. 96   124. 28   143. 16  
last close:  2. 85   102. 75   129. 63  
50-day avg:  3. 18   98. 90   122. 76  
200-day avg:  7. 97   100. 04   123. 17  
1-yr low:  2. 33   78. 22   100. 14  
volume:  568. 06 K 2. 36 M 4. 94 M
50-day avg volume:  373. 83 K 3. 14 M 4. 85 M
200-day avg volume:  763. 27 K 3. 12 M 4. 26 M

1-day return:  -5. 32 % 1. 74 % 0. 96 %
this week return:  7. 55 % -0. 72 % -0. 25 %
12-wk return:  -58. 52 % 1. 23 % -0. 75 %
52-wk return:  -79. 88 % -2. 03 % 16. 23 %

enterprise value (EV):  -10. 43 M 54. 82 B 107. 48 B
market cap:  77. 47 M 47. 12 B 97. 54 B
EBITDA:  -58. 64 M 4. 72 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 18   9. 03   16. 84  
enterprise/revenue (EV/R):  -14. 17   31. 24   24. 21  
total revenue:  736. 00 K 11. 05 B 40. 03 B
total debt:  0. 00   13. 41 B 16. 70 B
net income (common):  -62. 66 M 2. 34 B 3. 61 B

shares outstanding:  27. 18 M 594. 48 M 1. 22 B
shares:  19. 38 M 592. 96 M 1. 15 B
shares short:  675. 83 K 10. 54 M 11. 92 M
shares short prior month:  756. 32 K 11. 90 M 11. 87 M
short ratio:  1. 50   4. 86   3. 18  
short % of float:  3. 57 % 6. 23 % 2. 78 %
total cash/share:  3. 03   11. 99   10. 04  
total cash:  82. 46 M 7. 30 B 7. 05 B
free cash flow:  -26. 58 M 176. 15 M 2. 43 B
operating cash flow:  -51. 94 M 277. 94 M 3. 06 B

book value:  2. 75   15. 06   28. 80  
price/book:  1. 03   -0. 58   -2. 51  
gross profits:  -18. 52 M 8. 33 B 19. 31 B
operating margins:  -8045. 92 % -466. 96 % -635. 17 %
EBITDA margins:  0. 00 % 13. 54 % 22. 51 %
profit margins:  0. 00 % 6. 67 % 10. 02 %
gross margins:  0. 00 % 48. 21 % 54. 28 %

1-yr max volatility:  -39. 70 % --- ---
1-yr mean volatility:  -0. 42 % 0. 01 % 0. 07 %

1-yr EPS:  -2. 46   3. 08   4. 11  
forward EPS:  -2. 26   4. 75   7. 18  
P/E:  -1. 16   15. 54   29. 27  
forward P/E:  -1. 26   -20. 90   3. 33  
PE/G:  0. 10   1. 33   6. 07  
growth:  -11. 60 % 755. 42 % 114. 65 %
earnings high:  -0. 45   1. 33   1. 68  
earnings avg:  -0. 51   0. 97   1. 54  
earnings low:  -0. 59   0. 70   1. 41  
revenue high:  100. 00 K 2. 81 B 11. 37 B
revenue avg:  40. 00 K 2. 70 B 11. 06 B
revenue low:  -0. 00   2. 61 B 10. 84 B
return on assets:  -47. 46 % -3. 63 % 3. 73 %
return on equity:  -91. 51 % 102. 34 % 26. 90 %
revenue growth:  -11. 60 % 717. 29 % 107. 00 %
revenue/share:  0. 03   14. 67   60. 08  

beta (1yr vs S&P500):  2. 26   1. 22   0. 94  
sharpe (1yr):  -1. 00   0. 14   1. 05  

held % insiders:  20. 71 % 6. 40 % 3. 16 %
held % institutions:  46. 47 % 79. 62 % 70. 81 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-22 : IDRA
.        + 0 =             0 :: INITIAL WEIGHT
.  + 396.202 =       396.202 :: inverse volume-to-price addition
.   + 118.29 =       514.492 :: spline projection addition
.  - 242.844 =       271.648 :: poor performance penalty
.    x 0.498 =       135.239 :: one-year gains+dividend factor
.    x 5.517 =       746.067 :: 13 weeks' performance factor
.    x 1.478 =      1102.645 :: industry recommendation factor
.    x 0.995 =      1097.412 :: return on assets factor
.    x 0.991 =       1087.37 :: return on equity factor
.    x 0.999 =      1086.109 :: revenue growth factor
.    x 2.496 =      2710.469 :: current ratio factor
.    x 1.069 =      2897.484 :: quick ratio factor
.    x 1.291 =      3740.636 :: short ratio factor
.     x 2.01 =      7519.967 :: price-to-book factor
.     x 1.01 =        7593.7 :: EBITDA multiple vs industry factor
.    x 5.672 =     43070.114 :: EBITDA multiple factor
.    x 2.158 =     92961.039 :: P/E weight
.    x 1.779 =     165362.88 :: PE/G factor
.    x 1.393 =    230312.441 :: beta factor
.    x 0.996 =    229483.384 :: sharpe factor
.    x 1.811 =    415643.451 :: target low factor
.    x 0.894 =    371635.219 :: target mean factor
.    x 1.035 =    384658.741 :: target high factor
.    x 1.012 =    389394.646 :: industry 12-weeks return
.    x 0.908 =    353431.816 :: "drift" penalty 4 days ago
.    x 0.899 =    317752.194 :: "drift" penalty 5 days ago
.    x 0.998 =    317136.783 :: overall "drift" factor
.    x 0.998 =    316584.617 :: largest single-day jump factor
.     x 0.07 =     22092.437 :: low price factor
.      x 1.0 =     22090.147 :: factor hist industry gain for week 07
.   cubeRoot =        28.059 :: reduced for readability
.                     28.059 :: FINAL WEIGHT for NASDAQ:IDRA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org